SOLICITATION NOTICE
Q -- Assessment of prescription medications and risk of primary liver cancer
- Notice Date
- 8/2/2012
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-120158-MD
- Archive Date
- 8/31/2012
- Point of Contact
- Miguel Diaz, Phone: (301) 402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
miguel.diaz@nih.gov, cr214i@nih.gov
(miguel.diaz@nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6079, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG) plans to procure on a sole source basis with Boston University of 25 Buick St Boston, MA 02215 to assess prescription medications and their associated risk with primary liver cancer. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System Code is 621511 and the business size standard is $13.5 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. It has been determined that there is no opportunity to acquire Green Products or Services under this contract. The period of performance shall be twelve (12) months from date of award. Liver cancer, particularly hepatocellular carcinoma (HCC), is the fifth most frequently occurring cancer worldwide and the third most common cause of cancer mortality. HCC incidence has increased five-fold in the U.S. since the early 1980s. Reasons for this increase are not completely understood but are likely related to the increased prevalence of hepatitis C virus in the population and to the growing epidemics of obesity and diabetes. These risk factors, as well as other liver cancer risk factors cause chronic hepatic inflammation which can progress to fatty liver disease, fibrosis, cirrhosis, and eventually, liver cancer. Whether drugs that suppress inflammation or interfere with the progression from inflammation to liver cancer, or can otherwise prevent the development of liver cancer is not clear, although early studies have been promising. The acquisition will involve analysis of data from a licensed copy of the UK Clinical Practice Research Datalink (CPRD). The goal will be to conduct a series of nested case control studies to examine the associations between use of certain commonly used medications (non-steroidal anti-inflammatory drugs, anti-diabetic drugs, statins, anti-hypertensives, bisphosphonates, and estrogens) and the subsequent development of liver cancer. The Boston Collaborative Drug Surveillance Program (BCDSP), established in 1966, is one of the first and most widely published groups that conducts formal epidemiologic research to quantify the potential adverse effects of prescription drugs and had a pioneering role in the development and application of methods in drug epidemiology. Today the BCDSP, which has an unrestricted licensed copy of the CPRD, conducts major collaborative studies in the field of pharmacoepidemiology. The BCDSP has made a major contribution to the development and validation of the CPRD and has unique experience in the design and execution of pharmacoepidemiological studies with this database, a major resource for conducting drug safety studies. The BCDSP has published more than 400 pharmacoepidemiological studies and methodological reviews in peer-reviewed medical journals of which more than 150 are based on data from the CPRD. BCDSP has professional experience in linking, analyzing and publishing data on pharmacoepidemiology from large observational databases and the capacity to conduct large population-based assessments of prescription medications linked to liver cancer outcomes. BCDSP is the only known group that can provide the analysis of the CPRD data using globally-validated standards of research conduct and utilizing the licensed copy of CPRD. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on August 16, 2012. No electronic capability statements will be accepted (i.e. email or fax); an original and one copy must be sent to the NCI Office of Acquisitions to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Miguel Diaz, Contract Specialist at miguel.diaz@nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-120158-MD on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-120158-MD/listing.html)
- Record
- SN02824242-W 20120804/120802235732-a01738752b6c5dd3bdbc1b1991cbd8d3 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |